INdividualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT)
Patrick Wen, MD
460 participants
Feb 9, 2017
INTERVENTIONAL
Conditions
Summary
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM). The drugs involved in this study are : * Abemaciclib (arm is currently closed to accrual) * Temozolomide (temodar) * Neratinib (arm is currently closed to accrual) * CC115 (arm is currently closed to accrual) * QBS10072S
Eligibility
Plain Language Summary
Simplified for easier understanding
This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.
Interested in this trial?
Get notified about updates and connect with the research team.
Interventions
Temzolomide capsules
Neratinib tablets
QBS10072S administered intravenously
Abemaciclib tablets
CC-115 tablets
Locations(12)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT02977780